WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN
Aim. To compare effectiveness of non-drug therapy together with menopausal hormonal therapy (MHT) — estradiol hemihydrate 1 mg/drospirenon 2 mg (Angeliq® Bayer Pharma AG (Germany)) related to normalization of anthropometric and metabolic parameters, elasticity values and vascular age in women with m...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2016-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/706 |
| _version_ | 1797856979692027904 |
|---|---|
| author | V. Yu. Khripaeva I. N. Barykina A. S. Salasyuk V. O. Smirnova R. V. Palashkin S. V. Nedogoda |
| author_facet | V. Yu. Khripaeva I. N. Barykina A. S. Salasyuk V. O. Smirnova R. V. Palashkin S. V. Nedogoda |
| author_sort | V. Yu. Khripaeva |
| collection | DOAJ |
| description | Aim. To compare effectiveness of non-drug therapy together with menopausal hormonal therapy (MHT) — estradiol hemihydrate 1 mg/drospirenon 2 mg (Angeliq® Bayer Pharma AG (Germany)) related to normalization of anthropometric and metabolic parameters, elasticity values and vascular age in women with metabolic syndrome (MS) in postmenopause.Material and methods. The open-label prospective comparative controlled randomized study in 2 parallel groups. Sixty female patients (mean age 55,26±5,63 y.) with MS (according to IDF 2005 criteria) were randomized equally 1:1 into 2 groups. During 36 weeks patients of 1st group (n=30) received life style modification recommendations and monotherapy by Angeliq® , patients from 2nd group (controls, n=30) only followed life style modification. Groups were comparable by baseline clinical and demographic parameters. All patients received instructions for diet, physical activity and life style changes. Anthropometric, metabolic and instrumental assessments were done at baseline, in 12 and 36 weeks of therapy.Results. Prescription of MHT in MS patients in postmenopause led to body weight decrease, decrease of percent composition of visceral fat, improvement of metabolic parameters, vascular elasticity and decrease of vascular age. There were no adverse events related to the drug during the study.Conclusion. Angeliq® is effective and safe medication for low-dosage continuous combination MHT in menopausal MS that facilitates improvement of anthropometric parameters, vascular elasticity and vascular ageing. |
| first_indexed | 2024-04-09T20:49:15Z |
| format | Article |
| id | doaj.art-cc73594533c64a2fbfb76775adabad14 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:49:15Z |
| publishDate | 2016-04-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-cc73594533c64a2fbfb76775adabad142023-03-29T21:23:26Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202016-04-0104707510.15829/1560-4071-2016-4-70-75623WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMENV. Yu. Khripaeva0I. N. Barykina1A. S. Salasyuk2V. O. Smirnova3R. V. Palashkin4S. V. Nedogoda5Volgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityAim. To compare effectiveness of non-drug therapy together with menopausal hormonal therapy (MHT) — estradiol hemihydrate 1 mg/drospirenon 2 mg (Angeliq® Bayer Pharma AG (Germany)) related to normalization of anthropometric and metabolic parameters, elasticity values and vascular age in women with metabolic syndrome (MS) in postmenopause.Material and methods. The open-label prospective comparative controlled randomized study in 2 parallel groups. Sixty female patients (mean age 55,26±5,63 y.) with MS (according to IDF 2005 criteria) were randomized equally 1:1 into 2 groups. During 36 weeks patients of 1st group (n=30) received life style modification recommendations and monotherapy by Angeliq® , patients from 2nd group (controls, n=30) only followed life style modification. Groups were comparable by baseline clinical and demographic parameters. All patients received instructions for diet, physical activity and life style changes. Anthropometric, metabolic and instrumental assessments were done at baseline, in 12 and 36 weeks of therapy.Results. Prescription of MHT in MS patients in postmenopause led to body weight decrease, decrease of percent composition of visceral fat, improvement of metabolic parameters, vascular elasticity and decrease of vascular age. There were no adverse events related to the drug during the study.Conclusion. Angeliq® is effective and safe medication for low-dosage continuous combination MHT in menopausal MS that facilitates improvement of anthropometric parameters, vascular elasticity and vascular ageing.https://russjcardiol.elpub.ru/jour/article/view/706drospirenonmetabolic syndromemenopausal hormonal therapypostmenopausevascular elasticityvascular age |
| spellingShingle | V. Yu. Khripaeva I. N. Barykina A. S. Salasyuk V. O. Smirnova R. V. Palashkin S. V. Nedogoda WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN Российский кардиологический журнал drospirenon metabolic syndrome menopausal hormonal therapy postmenopause vascular elasticity vascular age |
| title | WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN |
| title_full | WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN |
| title_fullStr | WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN |
| title_full_unstemmed | WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN |
| title_short | WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN |
| title_sort | ways of menopausal hormonal therapy in correction of metabolic disorders and angioprotection in postmenopausal women |
| topic | drospirenon metabolic syndrome menopausal hormonal therapy postmenopause vascular elasticity vascular age |
| url | https://russjcardiol.elpub.ru/jour/article/view/706 |
| work_keys_str_mv | AT vyukhripaeva waysofmenopausalhormonaltherapyincorrectionofmetabolicdisordersandangioprotectioninpostmenopausalwomen AT inbarykina waysofmenopausalhormonaltherapyincorrectionofmetabolicdisordersandangioprotectioninpostmenopausalwomen AT assalasyuk waysofmenopausalhormonaltherapyincorrectionofmetabolicdisordersandangioprotectioninpostmenopausalwomen AT vosmirnova waysofmenopausalhormonaltherapyincorrectionofmetabolicdisordersandangioprotectioninpostmenopausalwomen AT rvpalashkin waysofmenopausalhormonaltherapyincorrectionofmetabolicdisordersandangioprotectioninpostmenopausalwomen AT svnedogoda waysofmenopausalhormonaltherapyincorrectionofmetabolicdisordersandangioprotectioninpostmenopausalwomen |